Spots Global Cancer Trial Database for stage iv squamous cell lung carcinoma ajcc v7
Every month we try and update this database with for stage iv squamous cell lung carcinoma ajcc v7 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02785939 | CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo... | Docetaxel Laboratory Biom... Palbociclib | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | NCT02766335 | Recurrent Squam... Stage IV Squamo... | Docetaxel Durvalumab Laboratory Biom... | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02785939 | CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo... | Docetaxel Laboratory Biom... Palbociclib | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP S1400K: c-MET Positive | NCT03574753 | Recurrent Squam... Stage IV Squamo... | ABBV-399 | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | NCT02785952 | Recurrent Squam... Stage IV Squamo... | Ipilimumab Laboratory Biom... Nivolumab Quality-of-Life... Questionnaire A... | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP S1400K: c-MET Positive | NCT03574753 | Recurrent Squam... Stage IV Squamo... | ABBV-399 | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer | NCT03377556 | ATM Gene Mutati... ATR Gene Mutati... BARD1 Gene Muta... BRCA1 Gene Muta... BRCA2 Gene Muta... BRIP1 Gene Muta... CHEK1 Gene Muta... CHEK2 Gene Muta... FANCA Gene Muta... FANCC Gene Muta... FANCD2 Gene Mut... FANCF Gene Muta... FANCM Gene Muta... NBN Gene Mutati... PALB2 Gene Muta... RAD51 Gene Muta... RAD51B Gene Mut... RAD54L Gene Mut... Recurrent Squam... RPA1 Gene Mutat... Stage IV Squamo... | Laboratory Biom... Pharmacological... Talazoparib | - | SWOG Cancer Research Network | |
| Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02965378 | FGFR1 Gene Ampl... FGFR1 Gene Muta... FGFR2 Gene Ampl... FGFR2 Gene Muta... FGFR3 Gene Ampl... FGFR3 Gene Muta... Recurrent Squam... Stage IV Squamo... | Docetaxel FGFR Inhibitor ... Laboratory Biom... | 25 Years - | SWOG Cancer Research Network | |
| Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer | NCT03373760 | Recurrent Squam... Stage IV Squamo... | Durvalumab Laboratory Biom... Tremelimumab | - | SWOG Cancer Research Network | |
| Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers | NCT02766335 | Recurrent Squam... Stage IV Squamo... | Docetaxel Durvalumab Laboratory Biom... | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | NCT02926638 | MET Positive Recurrent Squam... Stage IV Squamo... | Erlotinib Hydro... Laboratory Biom... Rilotumumab | 18 Years - | SWOG Cancer Research Network | |
| Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer | NCT02785939 | CCND1 Gene Ampl... CCND2 Gene Ampl... CCND3 Gene Ampl... CDK4 Gene Ampli... Recurrent Squam... Stage IV Squamo... | Docetaxel Laboratory Biom... Palbociclib | 18 Years - | SWOG Cancer Research Network |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
